Loading...
•
Jun 30
Zevra Q2 2025 Earnings Report
Zevra delivered a profitable Q2 2025, driven by MIPLYFFA sales and a one-time PRV voucher sale, despite recording a non-cash impairment charge.
Key Takeaways
Zevra reported Q2 2025 revenue of $25.9M, supported by $21.5M in MIPLYFFA sales and $2.6M in reimbursements for arimoclomol from France’s EAP. Net income surged to $74.7M due to a $148.3M gain from PRV sale, offset partially by a $58.7M impairment charge.
Total revenue reached $25.9M, including $21.5M from MIPLYFFA and $2.6M from French EAP reimbursements.
Net income was $74.7M, driven by a $148.3M gain from PRV sale.
Zevra recognized a $58.7M non-cash impairment charge related to OLPRUVA.
Cash, cash equivalents, and securities rose to $217.7M as of June 30, 2025.
Zevra
Zevra
Zevra Revenue by Segment
Revenue by Segment
MIPLYFFA Net Revenue
CapyFin.comOLPRUVA Net Revenue
CapyFin.comFrench EAP Arimoclomol Revenue
CapyFin.comAZSTARYS License Revenue
CapyFin.comDextrorphan Upfront Revenue
CapyFin.com Forward Guidance
Zevra expects continued growth driven by MIPLYFFA commercial traction and potential EMA approval for arimoclomol, while managing costs from launch and R&D activities.
Positive Outlook
- MIPLYFFA launch showing steady prescription growth
- EMA submission for arimoclomol completed on schedule
- Strong liquidity following PRV sale ($150M)
- OLPRUVA coverage expanded to 79% of lives
- Celiprolol DiSCOVER trial progressing with 39 enrolled patients
Challenges Ahead
- Recorded $58.7M non-cash impairment for OLPRUVA
- Inventory obsolescence expense of $11.7M impacted margins
- Operating loss of $71M despite high revenue
- OLPRUVA patient adoption remains low
- SG&A expenses increased significantly to support launches